Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Development and Validation of 18F-FDG PET/CT-Based Multivariable Clinical Prediction Models for the Identification of Malignancy-Associated Hemophagocytic Lymphohistiocytosis

  • Xu Yang (Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University) ;
  • Xia Lu (Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University) ;
  • Jun Liu (Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University) ;
  • Ying Kan (Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University) ;
  • Wei Wang (Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University) ;
  • Shuxin Zhang (Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University) ;
  • Lei Liu (Sinounion Medical Technology (Beijing) Co., Ltd.) ;
  • Jixia Li (Department of Laboratory Medicine, School of Medicine, Foshan University) ;
  • Jigang Yang (Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University)
  • Received : 2021.09.20
  • Accepted : 2021.12.26
  • Published : 2022.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: 18F-fluorodeoxyglucose (FDG) PET/CT is often used for detecting malignancy in patients with newly diagnosed hemophagocytic lymphohistiocytosis (HLH), with acceptable sensitivity but relatively low specificity. The aim of this study was to improve the diagnostic ability of 18F-FDG PET/CT in identifying malignancy in patients with HLH by combining 18F-FDG PET/CT and clinical parameters. Materials and Methods: Ninety-seven patients (age ≥ 14 years) with secondary HLH were retrospectively reviewed and divided into the derivation (n = 71) and validation (n = 26) cohorts according to admission time. In the derivation cohort, 22 patients had malignancy-associated HLH (M-HLH) and 49 patients had non-malignancy-associated HLH (NM-HLH). Data on pretreatment 18F-FDG PET/CT and laboratory results were collected. The variables were analyzed using the Mann-Whitney U test or Pearson's chi-square test, and a nomogram for predicting M-HLH was constructed using multivariable binary logistic regression. The predictors were also ranked using decision-tree analysis. The nomogram and decision tree were validated in the validation cohort (10 patients with M-HLH and 16 patients with NM-HLH). Results: The ratio of the maximal standardized uptake value (SUVmax) of the lymph nodes to that of the mediastinum, the ratio of the SUVmax of bone lesions or bone marrow to that of the mediastinum, and age were selected for constructing the model. The nomogram showed good performance in predicting M-HLH in the validation cohort, with an area under the receiver operating characteristic curve of 0.875 (95% confidence interval, 0.686-0.971). At an appropriate cutoff value, the sensitivity and specificity for identifying M-HLH were 90% (9/10) and 68.8% (11/16), respectively. The decision tree integrating the same variables showed 70% (7/10) sensitivity and 93.8% (15/16) specificity for identifying M-HLH. In comparison, visual analysis of 18F-FDG PET/CT images demonstrated 100% (10/10) sensitivity and 12.5% (2/16) specificity. Conclusion: 18F-FDG PET/CT may be a practical technique for identifying M-HLH. The model constructed using 18F-FDG PET/CT features and age was able to detect malignancy with better accuracy than visual analysis of 18F-FDG PET/CT images.

Keywords

Acknowledgement

Jigang Yang was supported by National Natural Science Foundation of China (No. 81971642,81771860), Beijing Natural Science Foundation (No. 7192041), National Key Research and Development Plan (No. 2020YFC0122000).

References

  1. Al-Samkari H, Berliner N. Hemophagocytic lymphohistiocytosis. Annu Rev Pathol 2018;13:27-49 
  2. Daver N, McClain K, Allen CE, Parikh SA, Otrock Z, Rojas-Hernandez C, et al. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer 2017;123:3229-3240 
  3. Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet 2014;383:1503-1516 
  4. Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc 2014;89:484-492 
  5. Tabata C, Tabata R. Possible prediction of underlying lymphoma by high sIL-2R/ferritin ratio in hemophagocytic syndrome. Ann Hematol 2012;91:63-71 
  6. Li F, Li P, Zhang R, Yang G, Ji D, Huang X, et al. Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. Med Oncol 2014;31:902 
  7. Jiang T, Ding X, Lu W. The prognostic significance of Beta2 microglobulin in patients with hemophagocytic lymphohistiocytosis. Dis Markers 2016;2016:1523959 
  8. Yoon SE, Eun Y, Huh K, Chung CR, Yoo IY, Cho J, et al. A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study. Ann Hematol 2020;99:2095-2104 
  9. Zheng Y, Hu G, Liu Y, Ma Y, Dang Y, Li F, et al. The role of 18F-FDG PET/CT in the management of patients with secondary haemophagocytic lymphohistiocytosis. Clin Radiol 2016;71:1248-1254 
  10. Yuan L, Kan Y, Meeks JK, Ma D, Yang J. 18F-FDG PET/CT for identifying the potential causes and extent of secondary hemophagocytic lymphohistiocytosis. Diagn Interv Radiol 2016;22:471-475 
  11. Wang J, Wang D, Zhang Q, Duan L, Tian T, Zhang X, et al. The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable. J Cancer Res Clin Oncol 2016;142:859-871 
  12. Kim J, Yoo SW, Kang SR, Bom HS, Song HC, Min JJ. Clinical implication of F-18 FDG PET/CT in patients with secondary hemophagocytic lymphohistiocytosis. Ann Hematol 2014;93:661-667 
  13. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-131 
  14. Cazzola M. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood 2016;127:2361-2364 
  15. Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood 2020;135:1332-1343 
  16. La Rosee P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019;133:2465-2477 
  17. Boddu P, Oviedo SP, Rausch CR, Yam C, Daver N, Kantarjian H, et al. PET-CT in AML-related hemophagocytic lymphohistiocytosis. Leuk Lymphoma 2018;59:1486-1489 
  18. Shieh AC, Guler E, Smith DA, Tirumani SH, Beck RC, Ramaiya NH. Hemophagocytic lymphohistiocytosis: a primer for radiologists. AJR Am J Roentgenol 2020;214:W11-W19 
  19. Yang YQ, Ding CY, Xu J, Fan L, Wang L, Tian T, et al. Exploring the role of bone marrow increased FDG uptake on PET/CT in patients with lymphoma-associated hemophagocytic lymphohistiocytosis: a reflection of bone marrow involvement or cytokine storm? Leuk Lymphoma 2016;57:291-298 
  20. Merrill SA, Naik R, Streiff MB, Shanbhag S, Lanzkron S, Braunstein EM, et al. A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis. Medicine (Baltimore) 2018;97:e11579 
  21. Hao R, Yang X, Liu Z, Yang J. EBV-associated T-cell lymphoproliferative disorders demonstrated on FDG PET/CT in a patient with hemophagocytic lymphohistiocytosis. Clin Nucl Med 2019;44:829-830 
  22. Pan Q, Luo Y, Wu H, Ma Y, Li F. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis mimicking lymphoma on FDG PET/CT. Clin Nucl Med 2018;43:125-127 
  23. Lu J, Fang Q, Ma C, Su F, Chen G, Huang M, et al. Atypical Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis simulating lymphadenitis on 18F-FDG PET/CT and its differential diagnosis. Hell J Nucl Med 2017;20:254-257 
  24. Zhang LJ, Xu J, Liu P, Ding CY, Li JY, Qiu HX, et al. The significance of 18F-FDG PET/CT in secondary hemophagocytic lymphohistiocytosis. J Hematol Oncol 2012;5:40 
  25. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 2005;117:104-111 
  26. Deme D, Telekes A. Prognostic importance of plasma C-reactive protein (CRP) in oncology. Orv Hetil 2017;158:243-256 
  27. Chen Y, Wang Z, Luo Z, Zhao N, Yang S, Tang Y. Comparison of Th1/Th2 cytokine profiles between primary and secondary haemophagocytic lymphohistiocytosis. Ital J Pediatr 2016;42:50 
  28. Ohno T, Ueda Y, Nagai K, Takahashi T, Konaka Y, Takamatsu T, et al. The serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: a comparative analysis of B-cell and T-cell/natural killer cell lymphomas. Int J Hematol 2003;77:286-294 
  29. Xu XJ, Tang YM, Song H, Yang SL, Xu WQ, Zhao N, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr 2012;160:984-990.e1 
  30. Weiss ES, Girard-Guyonvarc'h C, Holzinger D, de Jesus AA, Tariq Z, Picarsic J, et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood 2018;131:1442-1455 
  31. Tsuji T, Hirano T, Yamasaki H, Tsuji M, Tsuda H. A high sIL-2R/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann Hematol 2014;93:821-826 
  32. Cronin CG, Swords R, Truong MT, Viswanathan C, Rohren E, Giles FJ, et al. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol 2010;194:W91-W103